Aptalis is a wholly owned subsidiary of Allergan plc. Aptalis has manufacturing sites in Canada, Italy, the US, and France. Aptalis was formed in 2011 after the acquisition of Eurand Pharmaceuticals by Montreal-based Axcan Pharma. Axcans area of specialty was the treatment of gastrointestinal disorders. Formerly traded publicly on NASDAQ, Axcan was acquired by TPG Capital in 2008. Eurand Pharmaceuticals was a producer and contract manufacturer of modified release or taste-masked pharmaceutical dosage forms. Eurands former manufacturing facilities in Vandalia, Ohio and Milan, Italy continued to operate under the Aptalis name. Both Axcan and Eurand produced and marketed versions of the drug pancrelipase, which is used in the treatment of symptoms related to cystic fibrosis.